Apimeds Pharmaceuticals US, Inc. Statistics
Apimeds Pharmaceuticals US, Inc. (APUS) Stock Statistics & Valuation Metrics
Total Valuation
Apimeds Pharmaceuticals US, Inc. has a market cap or net worth of $3.37M. The enterprise value is $10.20T.
- Market Cap
- $3.37M
- Enterprise Value
- $10.20T
Share Statistics
Apimeds Pharmaceuticals US, Inc. has 1,509,118 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,509,118
- Owned by Insiders
- ―
- Owned by Institutions
- 0.72%
Financial Efficiency
Apimeds Pharmaceuticals US, Inc.’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -7.39%.
- Return on Equity (ROE)
- -0.04
- Return on Assets (ROA)
- -0.04
- Return on Invested Capital (ROIC)
- -7.39%
- Return on Capital Employed (ROCE)
- -0.08
- Revenue Per Employee
- 0
- Profits Per Employee
- -857.31K
- Employee Count
- 7
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Apimeds Pharmaceuticals US, Inc. is -0.04. Apimeds Pharmaceuticals US, Inc.’s PEG ratio is 0.00.
- PE Ratio
- -0.04
- PS Ratio
- 0.00
- PB Ratio
- 0.03
- Price to FCF
- -0.22
- Price to Operating Cash Flow
- -0.24
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Apimeds Pharmaceuticals US, Inc. had revenue of 0 and earned -6.00M in profits. Earnings per share was -5.50.
- Revenue
- 0
- Gross Profit
- -5,706
- Operating Income
- -11.91M
- Pretax Income
- -6.00M
- Net Income
- -6.00M
- EBITDA
- -5.71M
- Earnings Per Share (EPS)
- -5.50
Cash Flow
In the last 12 months, operating cash flow was -13.86M and capital expenditures -53,369, giving a free cash flow of -13.92M billion.
- Operating Cash Flow
- -13.86M
- Free Cash Flow
- -13.92M
- Free Cash Flow per Share
- -8.52
Dividends & Yields
Apimeds Pharmaceuticals US, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -445.31%
- Earnings Yield
- -1720.19%
Stock Price Statistics
- Beta
- 2.17
- 52-Week Price Change
- -93.64%
- 50-Day Moving Average
- 3.44
- 200-Day Moving Average
- 9.94
- Relative Strength Index (RSI)
- 34.67
- Average Volume (3m)
- 3.75M
Financial Position
Apimeds Pharmaceuticals US, Inc. as a current ratio of 1.31, with Debt / Equity ratio of 5.06%
- Current Ratio
- 1.31
- Quick Ratio
- 1.31
- Debt to Market Cap
- 0.43
- Net Debt to EBITDA
- -1.07
- Interest Coverage Ratio
- -42.09
Taxes
In the past 12 months, Apimeds Pharmaceuticals US, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Apimeds Pharmaceuticals US, Inc. EV to EBITDA ratio is -0.32, with an EV/FCF ratio of -1.25.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.32
- EV to Free Cash Flow
- -1.25
- EV to Operating Cash Flow
- -1.26
Balance Sheet
Apimeds Pharmaceuticals US, Inc. has $278.37K in cash and marketable securities with $14.58M in debt, giving a net cash position of -$14.30M billion.
- Cash & Marketable Securities
- $278.37K
- Total Debt
- $14.58M
- Net Cash
- -$14.30M
- Net Cash Per Share
- -$9.48
- Tangible Book Value Per Share
- $65.19
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Apimeds Pharmaceuticals US, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -1063.72%

